Communicable E6 - “Sneaky viruses”: an update on hepatitis B & C before World Hepatitis Day
Responsible for 1.3 million deaths and 2.2 million new infections per year, viral hepatitis is the second leading cause of morbidity and mortality amongst all infectious diseases, just behind tubercul...
25 Heinä 202454min
Communicable E5 - Beauty is in the 'I' of the beholder: EUCAST updates
The ‘I’ (intermediate susceptibility) in a EUCAST-guided antibiogram never meant impending resistance to your antibiotic. It was never meant to make you find the one ‘S’ (invariably a carbapenem) and ...
15 Heinä 202438min
Communicable E4 - The BLING-3 trial & continuous beta-lactam infusion: should these results change your practice?
Hosts Angela Huttner & Erin McCreary welcome Prof. David Paterson (Singapore) and Prof. Josh Davis (Newcastle, Australia) to discuss the design and results of the BLING-3 trial, which compared continu...
1 Heinä 202444min
Communicable E3 - The new WHO Priority Pathogens List: which bugs to target first?
What are WHO's most wanted bacterial pathogens in 2024? Hosts Angela Huttner & Oana Sandulescu welcome guests Dr. Hatim Sati of the World Health Organisation (WHO) and Dr. Erin Duffy (CARB-X) to discu...
17 Kesä 202442min
Communicable E2 - Phage therapy: does it work and will we have access?
In this episode, hosts Josh Davis (Newcastle, Australia) and Angela Huttner (Geneva, Switzerland) interview the phage ‘microbiologist-clinician duo’, Drs. Shawna McCallin and Lorenz Leitner (Balgrist ...
3 Kesä 202454min
Communicable E1 - Late-breaker clinical trial results from ESCMID Global 2024: Should they change your practice?
CMI Communications editors Angela Huttner, Marc Bonten, and Erin McCreary discuss late-breaker clinical trials presented at ESCMID Global (ECCMID) in Barcelona, providing insights into the trials’ des...
10 Touko 202458min
